Company Overview and News
Tesla (TSLA) reported Q4 production and delivery numbers on January 3rd that were in line with my expectations. Tesla delivered 29,870 vehicles of which 15,200 were Model S, 13,120 were Model X, and 1,550 were Model 3. Model S and X deliveries continue to grow with a 27% increase over Q4 2016 and a 9% increase over Q3 2017.
Cougar Metals NL (ASX:CGM) is preparing to reveal details in relation its option agreement with DNI Metals Inc over the Toamasina Graphite Project in Madagascar.
Cougar Metals NL (ASX:CGM) has received positive results from the first-pass soil and rock chip sampling at the Solonopole Lithium Project in Brazil. The company’s shares were trading circa 12% higher intra-day, at $0.019.
Cougar Metals NL's (ASX:CGM) shares closed yesterday at $0.018, and the company has entered a trading halt this morning pending details of a capital raising. A month ago, shares could have been snapped up for just $0.006. Cougar has exposure to lithium and graphite. The halt will remain in place until the opening of trade on Friday 15th September 2017, or earlier if an announcement is made to the market.
TORONTO, ON / ACCESSWIRE / March 13, 2017 / DNI Metals Inc. (CSE: DNI) (FSE: DG7N) (OTC PINK: DMNKF) ("DNI" or the "Company"). DNI will deliver 2,320 metric tonnes of graphite to a customer's facility in the United States. Monthly Shipments will commence in July and completed by December 2017.
Cougar Metals NL (ASX:CGM) has identified four high-priority targets from a lithium pegmatite targeting study at its Solonopole Project in northern Brazil.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
12h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...